Atezolizumab for Urinary Tract Cancer

"This study has already wrapped up recruitment and is no longer looking for patients. The listing was created on November 30th, 2016 but was updated as recently as August 25th, 2022. There are 29 other trials currently underway for urologic neoplasms and 357 clinical trials that involve Atezolizumab if you are seeking additional studies to participate in."

"Atezolizumab has a long history, with the first study being conducted in 2008. The original sponsor of this research was Hoffmann-La Roche. After the initial trial involving 720 patients, Atezolizumab received approval for Phase 2 clinical trials. As of now, there are 357 ongoing studies taking place in 1665 cities and 74 countries."

"Atezolizumab is most commonly prescribed as a treatment for small cell lung cancer, however it has also been used to effectively treat other conditions such as non-small cell lung carcinoma and postoperative malignant neoplasms."

"Atezolizumab was first studied in 2008 and there have been 79 completed studies on the medication to date. There are currently 357 clinical trials underway, with a significant number of them taking place in Calgary, Alberta."

"Atezolizumab's safety is estimated to be a 3. This rating comes from the fact that this is a Phase 3 trial, signifying that not only is there some evidence of efficacy, but also multiple rounds of data affirming its safety."

"This particular clinical trial, which was created on November 30th 2016 and last updated on August 25th 2022, is not currently looking for patients. Although this study has completed recruitment, there are 386 other studies that participants can sign up for."

"There are a total of 5 enrolling patients for this study, which includes Tom Baker Cancer Centre-Calgary in Calgary, Royal Victoria Hospital in Barrie, and Queen Elizabeth II Health Sciences Centre in Halifax. Additionally, there are 5 other locations where this trial is taking place."